First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)
Latest Information Update: 26 Apr 2024
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms CheckRad-CD8
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 01 Mar 2024 Results predicting Machine Learning-assisted treatment response to induction chemo-immunotherapy based on the peripheral blood immune status, as part of the pre-planned translational research program,published in the Neoplasia
- 28 Aug 2023 Planned End Date changed from 1 Apr 2023 to 1 Jan 2024.